PDD Holdings Inc. American Depositary Shares vs Viatris Inc — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $79.19 (market cap $111.74B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: PDD Holdings Inc. American Depositary Shares is far larger — about 5.6× Viatris Inc's market cap, and Viatris Inc pays a 2.74% dividend while PDD Holdings Inc. American Depositary Shares pays none. Which is the better fit depends on your goals.
| PDD | VTRS | |
|---|---|---|
Market Cap | $111.74B | $20.12B |
Volume | 4,029,869 | 7,543,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $138.13 | $18.27 |
52-Week Low | $73.30 | $9.74 |
Enterprise Value | $44.39B | $32.24B |
Typical Hold Time | — | 57 Days |
Dividend Yield | — | 2.74% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
Latest headlines on both assets
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →